Efficacy and Safety of a Multistrain Probiotic Formulation Depends from Manufacturing
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: Variability in probiotics manufacturing may affect their properties, with potential implications for their efficacy and safety. This is of particular concern with probiotic products destined for use in patients with serious medical conditions, including HIV infection. The purpose of the study was to carry out a series of experiments comparing the properties of the US-made probiotic formulation originally commercialized under the brand name VSL#3®, with those of the Italian-made formulation now commercialized under the same name. The US-made formulation has previously shown beneficial effects at the intestinal and neurological levels in HIV-infected subjects as well as in patients with Inflammatory Bowel Diseases (IBD) and hepatic encephalopathy. Methods: Eleven subjects receiving combined antiretroviral therapy (cART) for HIV-1 were treated for 6 months with the US-made VSL#3 formulation. At baseline and 6 months, T-cells were analyzed for phenotype and activation markers, and fecal samples were analyzed for bifidobacteria, lactobacilli and their metabolites. The fecal metabolome was assessed using 1H-NMR spectroscopy. Production of metabolites of interest by bacteria obtained from sachets of the two formulations were compared in vitro and their effects on a rat intestinal epithelial cell line (IEC-6) were assessed. Particular attention was paid to the metabolite 1,3-dihydroxyacetone (DHA). Results: At 6 months fecal samples showed a significant increase in the specific bacterial genera contained in the probiotic supplement. Immune activation was reduced as shown by a significant reduction in the percentage of CD4+CD38+HLA-DR+ T-cells at 6 months. Fecal concentrations of DHA decreased significantly. In vitro, significant differences in the production and metabolism of DHA were found between bacteria from the US-made and Italian-made formulations: the US-made formulation was able to metabolize DHA whereas the bacteria in the Italian-made formulation were producing DHA. DHA reduced the viability of Staphylococcus thermophilus, reduced IEC-6 cell viability in a dose-dependent manner, and also led to a lower rate of repair to scratched IEC-6 cell monolayer. Conclusion: Our data, in conjunction with previously published findings, confirm that the new Italian –made formulation of VSL#3® is different from the previous US-made VSL#3 and therefore its efficacy and safety in HIV-infected subjects is still unproven.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of vaginal lactobacilli and characterization of anti-candida activity
Parolin, C., Marangoni, A., Laghi, L., Foschi, C., Ñahui Palomino, R. A., Calonghi, N., Cevenini, R., & Vitali, B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0131220 · Cited by 228
Self-citationMastromarino, P., Macchia, S., Meggiorini, L., Trinchieri, V., Mosca, L., Perluigi, M., & Midulla, C. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.02112.x · Cited by 194
Self-citationDe Filippis, F., Vannini, L., La Storia, A., Laghi, L., Piombino, P., Stellato, G., Serrazanetti, D. I., Gozzi, G., Turroni, S., Ferrocino, I., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112373 · Cited by 146
Self-citationd'Ettorre, G., Rossi, G., Scagnolari, C., Andreotti, M., Giustini, N., Serafino, S., Schietroma, I., Scheri, G. C., Fard, S. N., Trinchieri, V., et al. (2017) · Immunity, Inflammation and Disease · doi:10.1002/iid3.160 · Cited by 104 · cited 2×
“No adverse events were registered, and notably at the end of the trial all the subjects expressed the desire to continue dietary supplementation with the same probiotic preparation because they experienced a subjective improvement of wellness, as previously documented (4).”
Self-citationSalminen, M. K., Tynkkynen, S., Rautelin, H., Poussa, T., Saxelin, M., Ristola, M., Valtonen, V., & Järvinen, A. (2004) · HIV Clinical Trials · doi:10.1310/6f83-n39q-9ppp-lmvv · Cited by 103
Cited by
Gut Microbiome: Profound Implications for Diet and Disease
Hills, R., Pontefract, B., Mishcon, H., Black, C., Sutton, S., & Theberge, C. (2019) · Nutrients · doi:10.3390/nu11071613 · Cited by 1,092
The Unregulated Probiotic Market
de Simone, C. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.01.018 · Cited by 317
da Silva, T. F., Glória, R. D. A., Americo, M. F., Freitas, A. D. S., de Jesus, L. C. L., Barroso, F. A. L., Laguna, J. G., Coelho-Rocha, N. D., Tavares, L. M., le Loir, Y., et al. (2024) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-024-10247-x · Cited by 117
“It could harm the balance between anti-and pro-inflammatory cytokines and other cellular functions [355–357].”
Casado-Bedmar, M., & Viennois, E. (2022) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjab223 · Cited by 77
Metadata
- Authors
- Trinchieri, V., Laghi, L., Vitali, B., Parolin, C., Giusti, I., Capobianco, D., Mastromarino, P., & De Simone, C.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2017-11-06
- Volume
- 8
- Pages
- 1474-1474
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2765136130
- Cited by
- 52
- References
- 5
- FWCI
- 9.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of a Multistrain Probiotic Formulation Depends from Manufacturing. https://app.cochat.ai/papers/10.3389/fimmu.2017.01474
- The paper
- Trinchieri, V., Laghi, L., Vitali, B., Parolin, C., Giusti, I., Capobianco, D., Mastromarino, P., & De Simone, C. (2017). Efficacy and Safety of a Multistrain Probiotic Formulation Depends from Manufacturing. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2017.01474
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.